Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 5;79(11):1400–1413. doi: 10.1136/annrheumdis-2019-216761

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Number of baseline risk factors for patients who experienced a DVT, PE or ATE in completed studies in the (A) RA, (B) PsO and (C) PsA tofacitinib development programmes, stratified by tofacitinib dose. Those patients who had an event within the predefined risk period (minimum of a patient’s last treatment dose date plus 28 days, date of death or up to the last observation date) are included. Details on the individual risk factors, and the number of patients who experienced each risk factor, are summarised in online supplementary table S6. ATE, arterial thromboembolism; BID, twice daily; DVT, deep vein thrombosis; n, number of patients with a given number of baseline risk factors; PE, pulmonary embolism; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis.